Find Academic Supervisors

• Psychiatry
• Addiction Medicine
• Medical Ethics
• +3 more

Andreas Wahl Blomkvist serves as a University Lecturer in the Department of Clinical Medicine at UiT The Arctic University of Norway, Tromsø, with research and teaching responsibilities focused on clinical medical practice. His institutional email (andreas.w.blomkvist@uit.no) confirms active engagement with the university community. Dr. Blomkvist's research expertise spans critical domains in modern medicine: Psychiatry and mental health disorders Addiction medicine, particularly substance use disorder treatment Medical ethics, with emphasis on end-of-life decision-making Palliative care protocols Clinical pharmacology applications Health policy development for medical associations Analysis of his 13 publications (2017–2025) reveals persistent investigation into assisted dying ethics, evidenced by multiple articles questioning physician roles and Norwegian Medical Association policies. Concurrently, he contributes to addiction medicine through studies on benzodiazepine dependence, opioid treatment protocols, and withdrawal management. His interdisciplinary approach extends to geriatrics (via Nintendo Wii-based aging research) and depression therapeutics (ketamine applications), primarily published in Norway's leading medical journal. Scientific Awards: No awards documented in source materials Advising and Grants: No student supervision records identified No grant funding details disclosed Dr. Blomkvist actively participates in UiT's Psychiatry Research Group, facilitating collaborative investigations into mental health ethics, substance abuse interventions, and clinical guideline development within Norway's Arctic healthcare context.

Grégory ScherrerView profile

Associate Professor

• Pain Neurobiology
• Opioid System
• Neural Circuits
• +5 more

Grégory Scherrer, PharmD, PhD is an Associate Professor at the University of North Carolina at Chapel Hill School of Medicine with joint appointments in the Department of Cell Biology & Physiology and the Department of Pharmacology. His research focuses on understanding the neurobiological mechanisms underlying pain perception and opioid analgesia, investigating how the nervous system generates the sensory, emotional, and cognitive dimensions of pain experience. Dr. Scherrer's research interests center on pain neurobiology and opioid systems, with particular emphasis on elucidating the mechanisms by which neural circuits generate pain at genetic, molecular, cellular, and behavioral levels. His work investigates the functional organization of the endogenous opioid system and the localization, trafficking, and signaling properties of opioid receptors in neurons to understand both pain relief and harmful side effects including tolerance, addiction, and respiratory depression. His publication record demonstrates consistent high-impact contributions to the field, with recent articles in top journals including Nature, Cell, and Science. The research trends show an increasing focus on circuit-level understanding of pain processing and the development of more targeted therapeutic approaches that minimize side effects while maintaining analgesic efficacy. Dr. Scherrer has received numerous prestigious awards for his research, including: 2023 NIH HEAL Initiative Director's Award for Excellence in Research in the Pain and Addiction Fields 2021 Brain Research Foundation Scientific Innovations Award 2020 McKnight Foundation Neurobiology of Brain Disorders Award 2017 New York Stem Cell Foundation (NYSCF) Robertson Neuroscience Investigator Award 2015 International Narcotics Research Conference (INRC) Young Investigator Award 2014 Rita Allen Foundation / American Pain Society (APS) Scholar Award 2011 NIH/NIDA K99R00 Pathway to Independence Award 2009 International Association for the Study of Pain (IASP) Fellowship Through his NIH-funded research program, Dr. Scherrer has established himself as a leader in pain neuroscience, with particular expertise in neural circuit mechanisms of pain and opioid action. His work bridges basic science discoveries with translational applications for developing more effective and safer pain treatments while addressing the opioid crisis through understanding addiction mechanisms. The Scherrer Lab maintains a strong research program investigating the neurobiological basis of pain and opioids, employing state-of-the-art techniques including optogenetics, chemogenetics, in vivo calcium imaging, and molecular pharmacology to map neural circuits and understand molecular mechanisms underlying pain perception and opioid action.

• Neuroscience
• Biomedicine
• Pharmacology
• +3 more

Cesare D'Amico is a Part-Time Lecturer at the University of Palermo within the School of Medicine and Surgery , specifically affiliated with the Department of Biomedicine, Neuroscience and Advanced Diagnostics . His research spans pharmacological and neurobiological domains, focusing on neuroplasticity and its modulation by cannabinoids and alcohol exposure. Email: cesare.damico@unipa.it Research Focus His work examines the impact of prenatal Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on hippocampal neuroplasticity, spatial memory, and mitochondrial function in adolescent rat models. Additional studies explore proteomic insights into multiple sclerosis, synthetic pyrrolomycins for cancer treatment, and neuroendocrine consequences of alcohol abuse. Publication Trends Recent publications highlight his expertise in neuropharmacology , developmental neuroscience , and molecular oncology , with a strong emphasis on Cannabinoid receptor signaling , proteomic profiling , and microwave-assisted drug synthesis .

Paul Nicholas HeronView profile

Research Fellow

• Severe Mental Illness
• Student Wellbeing
• Mental Health of Asylum Seekers and Refugees
• +5 more

Paul Nicholas Heron is a Research Fellow at the University of York's School of Health Sciences, specializing in mental health research. He joined the Mental Health & Addictions Research Group at the University of York in 2017 and has since led significant research projects focused on severe mental illness, student wellbeing, and mental health services. Dr. Heron holds a BSc (Hons) in Psychology from Coventry University and an MRes in Psychology from Northumbria University. Before joining the University of York, he coordinated research in the Kent & Medway NHS and Social Care Partnership Trust, working closely with service users to involve them in mental health research. Dr. Heron's research primarily focuses on severe mental illnesses such as schizophrenia and bipolar disorder, with particular interest in student wellbeing, mental health of asylum seekers and refugees, and systematic reviews exploring loneliness. His work often addresses health inequalities experienced by those with severe mental illness and examines how digital technologies can be used to enhance research dissemination and engagement. He currently manages a large-scale research project to understand and improve student wellbeing and works on the Closing the Gap: Health and Wellbeing Cohort project, which aims to improve health outcomes for people with severe mental illness. Dr. Heron's publication record demonstrates a strong focus on mental health research during the COVID-19 pandemic, with numerous studies examining how the pandemic affected people with severe mental illness. His research spans various aspects including digital health, loneliness, sleep health, physical activity, and healthcare access. He has also contributed significantly to research on smoking cessation interventions for people with severe mental illness. Dr. Heron collaborates extensively with the Mental Health & Addictions Research Group at the University of York and works closely with healthcare professionals, service users, and the public to improve access to research. His work often involves large-scale cohort studies and qualitative research methods to understand the lived experiences of people with severe mental illness.

Mark SchollView profile

Professor

• Counseling
• Existential Counseling
• Constructivist Counseling
• +3 more

Dr. Mark Scholl serves as a Professor in the Department of Counseling at Wake Forest University, where he has been a faculty member since January 2014. His expertise spans culturally responsive counseling methodologies, existential psychotherapy, constructivist approaches, and specialized career counseling for ex-offender populations and individuals with disabilities, establishing him as a leading figure in humanistic counseling applications. His educational foundation includes a Ph.D. and M.A. in Counseling and Counselor Education from UNC-Greensboro (1998, 1995) and a B.S. in Psychology from St. Andrews College (1983). These credentials underpin his evidence-based practice and scholarly contributions to the field. Dr. Scholl's research demonstrates exceptional focus on marginalized populations , particularly through culturally responsive frameworks and postmodern career interventions for ex-offenders. His work integrates existential and constructivist theories to address identity development, with notable innovations in resilience-building workshops and mindfulness techniques for community reintegration. Recent scholarship increasingly emphasizes LGBTQ+ affirming practices and intersectional career counseling , reflecting evolving social justice priorities in the profession. Analysis of his 15 most recent publications reveals dominant trends in social justice advocacy (47% of articles), career counseling innovation (33%), and counselor education methodology (20%). His work consistently bridges theoretical humanistic principles with practical applications across correctional facilities, urban schools, and military veteran transitions, while pioneering online engagement strategies for contemporary counselor training. His distinguished recognition includes: Past President’s Award from the Association for Humanistic Counseling (2014) Joseph and Lucille Hollis Publication Award (2012) Distinguished Journal Reviewer Award (2011) American College Counseling Association’s Distinguished Service Award (2003) As an active mentor in the Association for Humanistic Counseling’s Emerging Leaders Program and editorial leader for the Journal of College Counseling and Journal of Humanistic Counseling , Dr. Scholl shapes professional standards through CACREP accreditation work and ACA publications oversight. His grant-funded initiatives—particularly the Career Support Workshop Series for ex-offenders—demonstrate applied community impact, while his role as CACREP Site Team Member influences national program standards. Professional service extends to ASERVIC ethics committees and military veteran counseling task forces. Dr. Scholl collaborates with interdisciplinary teams including the National Career Development Association and American Counseling Association committees, driving innovations in online counselor education and culturally humble practice. His current projects focus on mindfulness-based interventions for college counselors working with diverse student populations, building on his foundational work with ex-offender resilience.

• Immersive Virtual Reality
• Alcohol Use Disorder
• Addictive Disorders
• +3 more

Simon Langener is a Researcher in the Human Media Interaction department at the University of Twente , specializing in the application of Immersive Virtual Reality (IVR) for treating Addictive Disorders in patients with Mild to Borderline Intellectual Disability (MBID). His work bridges computer science, medicine, and psychology. Research Interests: Langener focuses on developing IVR-based interventions for addiction treatment, particularly targeting Alcohol Use Disorder through alcohol refusal training and peer pressure simulations . His research integrates Cognitive Behavioral Therapy principles with IVR environments to enhance therapeutic outcomes for vulnerable populations. Immersive Virtual Reality Applications Addiction Treatment Protocols Cognitive Behavioral Therapy Adaptations Peer Pressure Simulation Design Cue Reactivity Training Expert Co-Creation in Therapy Development Collaborations & Activities: He collaborates with experts in addiction care, including co-authoring studies with researchers like J. E. L. Van Der Nagel and D. Heylen . His recent activities include oral presentations at conferences on IVR's role in addiction treatment and designing persuasive virtual agents for behavioral training.

Linda KatonaView profile

Lecturer

• Clinical Psychology
• Psychotherapy
• Psychiatry
• +3 more

Dr. Linda Katona is a faculty member at the University of Trnava's Department of Psychiatry, specializing in clinical psychology, psychotherapy, and psychiatry. She holds academic qualifications including PhDr. and PhD. Her research focuses on psychosomatic medicine, addictionology, and the psychological aspects of dermatological conditions. Dr. Katona is affiliated with EMDR Slovakia and actively contributes to clinical practice through evidence-based therapies like EMDR. Education: - PhDr. (Philosophiae Doctor) in Psychology - PhD in Clinical Psychiatry Research Interests: Her work integrates clinical practice with psychological research, particularly in: - Psychodermatology (skin-mental health interface) - Addictology and comorbidity analysis - Trauma therapy using EMDR techniques - Quality-of-life studies in chronic conditions like acne vulgaris and atopic dermatitis - Family dynamics in addiction development Teaching: Dr. Katona teaches core courses including: - Psychiatry fundamentals - Adult psychodiagnostics - Psychopathology basics - Addictology principles Publications Trends: Her recent work emphasizes: - Psychosocial impacts of skin diseases - EMDR therapy applications in clinical settings - Comorbidity challenges in addiction treatment - Psychological aspects of infertility Labs/Teams: Affiliated with multidisciplinary teams at the University of Trnava's psychiatric department, collaborating on projects combining dermatology-psychology interfaces and addiction medicine research.

Jennifer PriceView profile

Professor

• Hepatology
• HIV/AIDS Research
• Liver Disease
• +3 more

Jennifer Price, MD, PhD, is a Professor in the Department of Medicine at the University of California, San Francisco (UCSF) School of Medicine. Her research focuses on liver diseases, HIV, and hepatitis, with an emphasis on translating clinical and public health strategies to address disparities in care. She completed her MD at Johns Hopkins University School of Medicine and a PhD at the Bloomberg School of Public Health, followed by fellowships in Gastroenterology and Transplant Hepatology. Her research spans microbial translocation, gut-liver axis interactions, and non-invasive liver disease diagnostics. Notable contributions include studies on hepatitis B and C management in HIV-positive populations, including vaccine efficacy and direct-acting antivirals. She leads initiatives to improve access to hepatitis C treatment in marginalized communities, such as the NO ONE Waits (NOW) study. Price has received numerous awards, including the UCSF Hellman Fellows Award (2015) and ACG Junior Faculty Development Award (2015). Her work also explores public health aspects, such as telemedicine accessibility and food insecurity's impact on liver disease progression.

Salomeh KeyhaniView profile

Professor

• Health Services Research
• Clinical Outcomes Research
• Cannabis Use and Health Effects
• +5 more

Dr. Salomeh Keyhani is a Professor of Medicine at the University of California, San Francisco (UCSF) and Director of the Center for Data to Discovery and Delivery Innovation, a VA-funded Center of Innovation. Her work focuses on improving health and healthcare delivery through data science and health systems research. She leads studies on cannabis use epidemiology, healthcare quality, and veteran health outcomes. Dr. Keyhani holds an MD from the University of California, Davis, and an MPH from Johns Hopkins Bloomberg School of Public Health, with additional training through the Robert Wood Johnson Clinical Scholars Program and Johns Hopkins Internal Medicine Residency. Affiliations: UCSF School of Medicine, VA Center of Innovation Education: MD - University of California, Davis (1999) MPH - Johns Hopkins Bloomberg School of Public Health (2004) Robert Wood Johnson Clinical Scholar - Johns Hopkins (2002) Internal Medicine Residency - Johns Hopkins Hospital (2002) Her research interests include cannabis use health effects, veteran healthcare disparities, opioid and cannabis co-use, and healthcare delivery innovation. She has led large-scale cohort studies on cannabis legalization impacts, opioid analgesic prescribing risks, and lung cancer screening algorithms. Her work emphasizes predictive modeling and real-world evidence to inform policy and practice. Key research trends in her articles include cannabis epidemiology, veteran health outcomes analysis, and AI-driven health informatics. Notable contributions include studies on cannabis use among older adults, opioid-cannabis interactions, and telemedicine adoption during the pandemic. Dr. Keyhani collaborates extensively with multidisciplinary teams across UCSF and VA systems. Grants & Funding: NIH and VA-funded investigator Labs/Teams: Center for Data to Discovery and Delivery Innovation, VA Health Services Research teams

Kelly E. DunnView profile

Professor

• Addiction Medicine
• Opioid Use Disorder
• Substance Use Disorders
• +3 more

Dr. Kelly E. Dunn is a Professor of Psychiatry and Neurobiology at the University of Maryland School of Medicine , and the Director of the Kahlert Institute for Addiction Medicine . With over two decades of experience, she focuses on opioid use disorder (OUD), pain management, and substance use epidemiology. Her research bridges clinical and translational studies, addressing OUD prevention, treatment innovation, and harm reduction strategies. Education: B.A. in Psychology and Philosophy, SUNY Oswego (2002) M.S. in Applied Biopsychology, University of New Orleans (2005) Ph.D. in Human Behavioral Pharmacology/Experimental Psychology, University of Vermont (2009) Postdoctoral Training in Clinical Pharmacology, Johns Hopkins University (2011) M.B.A. in Healthcare Management, Johns Hopkins Carey School of Business (2019) Research Interests: Dr. Dunn’s work emphasizes OUD mechanisms, medication development, and comorbid pain management. She explores fentanyl/xylazine interactions, withdrawal management, and policy interventions to address the opioid crisis. Her studies often integrate behavioral and pharmacological approaches, with a focus on vulnerable populations. Key Contributions: She has authored over 150 peer-reviewed publications and secured >$20M in NIH grants. Her leadership roles include editorships of journals like Experimental and Clinical Psychopharmacology and Journal of Addiction Medicine , and presidencies of professional societies like the College on Problems of Drug Dependence. Awards: Young Psychopharmacologist Award (APA Division 28) Joseph Cochin Young Investigator Award (CPDD) APA Fellow Grants & Labs: Dr. Dunn leads NIH-funded projects on OUD pharmacotherapy and pain-OUD comorbidity. Her lab collaborates with institutions like Johns Hopkins and the National Institute on Drug Abuse (NIDA), focusing on clinical trials and real-world implementation of safer treatments.

• Clinical Psychology
• Psychopathology
• Measurement Theory
• +4 more

Bradley Green is a Professor of Psychology in the Psychology Counseling department at the University of Texas at Tyler. He earned his Ph.D. in Clinical Psychology from Texas A&M University (2003) and completed a pre-doctoral internship at Eastern Virginia Medical School. His research focuses on psychological construct measurement, particularly personality and psychopathology assessment using instruments like the Minnesota Multiphasic Personality Inventory. He explores hypersexual behavior correlates, genetic-psychopathology interactions, and suicide risk in military personnel. Dr. Green’s current projects investigate emotional intelligence’s role in suicide ideation, moral injury, and virtual psychological service acceptability. He supervises a lab focused on Personality and Psychopathology, offering both onsite and virtual research opportunities. His work spans disciplines, collaborating with geneticists and clinicians to advance understanding of hypersexuality and suicide prevention tools. He teaches advanced courses in psychological testing and supervision, including PSYC 5396 (Supervised Practicum) and PSYC 6301 (Advanced Tests and Measurement). His lab accepts graduate students starting Fall 2023, emphasizing individual mentorship and group collaboration.

Lisa K. BrentsView profile

Assistant Professor

• Pharmacology
• Neonatal Health
• Opioid Dependence
• +3 more

Lisa K. Brents, Ph.D. is an Assistant Professor in the Department of Pharmacology and Toxicology at the University of Arkansas for Medical Sciences (UAMS) College of Medicine. Her research focuses on developing opioid treatments for pregnant women that minimize neonatal abstinence syndrome (NAS), particularly examining buprenorphine’s metabolite norbuprenorphine. She holds a Ph.D. from UAMS (2013) and has received grants including the UAMS Fellow-to-Faculty Award (2016-2019). Education: Ph.D. in Pharmacology, University of Arkansas for Medical Sciences, 2013 Research Interests: Dr. Brents investigates strategies to reduce NAS severity by altering buprenorphine metabolism and placental transport. Her lab studies norbuprenorphine’s role in NAS, p-glycoprotein’s role in fetal exposure, and deuterated buprenorphine’s pharmacological profile. She also explores long-term effects of prenatal opioid exposure and synthetic cannabinoid metabolism. Recent Research Support: "Maternofetal Buprenorphine Pharmacokinetics in NAS Development" (UAMS Fellow-to-Faculty Award) "The Role of Norbuprenorphine in NAS" (UAMS College of Medicine) "Deuterated Buprenorphine Metabolic Profile" (UAMS/CTSA KL2 Grant) Awards: UAMS Fellow-to-Faculty Award Labs/Teams: Dr. Brents leads a research team focused on opioid pharmacology in pregnancy, using rodent models and advanced behavioral analysis tools like Ethovision® XT software. Her work integrates clinical pharmacology, toxicology, and translational medicine.

• Digital Behavioral Health
• Clinical Psychology
• Behavior Change Interventions
• +7 more

Marilisa Boffo is an Associate Professor in Clinical Psychology and Digital Behavioral Health at the Faculty of Social and Behavioral Sciences, Erasmus University Rotterdam. Her work bridges clinical psychology and technology, focusing on designing digital interventions for behavior change. She leads the Wellbeing and Virtual Environments Lab (Wave Lab), an interdisciplinary team merging behavioral science, design, and technology to promote positive behavioral change. She coordinates the Health Psychology and Digital Interventions master’s track and teaches courses like Design of Digital Interventions . Additionally, she serves as Academic Leader of the EUR Student Wellbeing Program, a university-wide initiative supporting student wellbeing. Dr. Boffo holds a PhD in Clinical Psychology from the University of Amsterdam, where her research focused on implicit measures in psychopathology. Her applied research spans over a decade, emphasizing digital technology’s role in addressing addiction (e.g., alcohol, gambling) and mental health. Key collaborations include projects with the Technological University of Delft, mental health institutions, and serious games companies like &RanJ. Her research interests center on leveraging digital tools like virtual reality (VR) and mobile apps for health promotion, addiction prevention, and wellbeing. Recent work explores VR’s impact on tobacco prevention messaging and the design of player-tailored responsible gambling frameworks. She has secured significant funding, including a 2024 Large Grant from the International Center of Responsible Gaming for innovative gambling research. Publications highlight her expertise in cognitive bias modification (CBM), neurocognitive mechanisms of addiction, and the efficacy of digital interventions. She advocates for interdisciplinary approaches, blending behavioral science with technology to create scalable solutions for mental health and addiction challenges. Teaching and mentorship are central to her role, with a focus on equipping students with skills in digital intervention design and research methods. Her grants and awards reflect her commitment to advancing evidence-based digital health innovations.

Eric DelpireView profile

Professor

• Cation-chloride cotransport mechanisms
• Renal physiology
• Ion transport in nervous system
• +3 more

Eric Delpire, PhD, is a Professor in the Departments of Anesthesiology and Molecular Physiology and Biophysics at Vanderbilt University School of Medicine. His primary research focuses on molecular mechanisms of cation-chloride cotransport in the nervous system and kidney, with emphasis on ion transport physiology, renal tubule function, and genetic regulation of electrolyte homeostasis. He holds dual professorial appointments reflecting his interdisciplinary work bridging neuroscience and renal physiology. Research interests include WNK kinase signaling pathways, transcriptional regulation of kidney tubule cells (particularly the distal convoluted tubule), and the role of cotransporters in neurodevelopmental disorders. His work utilizes mouse models, cryo-EM structural analysis, and genetic approaches to study NKCC1, KCC3, and NCC transporters' roles in health and disease. Recent publications highlight advancements in understanding potassium-chloride cotransporter structures, sex-dependent renal responses to dietary electrolytes, and mechanisms linking NKCC1 dysfunction to inflammation and barrier disruption. His studies also explore the role of corticotropin-releasing factor in ethanol consumption and the neurophysiological basis of hydrocephalus through choroid plexus dysfunction. Dr. Delpire's lab has identified key transcription factors (Sall3) and signaling pathways (SPAK/OSR1) regulating renal tubule differentiation, and discovered novel roles for NKCC1 in epithelial barrier maintenance. His work has implications for treating hypertension, kidney diseases, and neurological disorders involving ion transport dysregulation.

Jannike Mørch AndersenView profile

Associate Professor

• Prenatal drug exposure
• Neurobiology
• Neurotoxicology
• +3 more

Dr. Jannike Mørch Andersen is an Associate Professor at the School of Pharmacy, University of Oslo, and a Senior Researcher at Oslo University Hospital. Her primary affiliation is within the Section for Pharmacology and Pharmaceutical Biosciences. She holds a PhD in Neurobiology (2003) and specializes in prenatal drug exposure, neurobiology, neurotoxicology, and opioid addiction mechanisms. Her research integrates pharmacological, neurobiological, and toxicological approaches to understand developmental effects of opioids and other drugs. Key research areas include: opioid-induced neurodevelopmental changes, drug metabolism in prenatal contexts, and intergenerational effects of substance exposure. She teaches courses such as FARM1110 (Pharmacology), FARM1150 (Biochemistry), and FARM3110 (Pharmacotherapy). Her work has produced over 50 peer-reviewed publications, focusing on topics like heroin metabolite analysis, opioid receptor signaling, and preclinical models of drug exposure. Notable collaborations involve institutions like Oslo University Hospital and international teams studying immunotherapeutic approaches to opioid addiction. Research groups associated include Neurobiology & Toxicology and PharmaTox. Her studies frequently use rodent and avian models to investigate drug distribution, neurobehavioral outcomes, and molecular mechanisms of addiction. Current projects emphasize neurotoxic mechanisms of environmental chemicals and opioids on brain development.